Clinical trials: sponsored by Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.
The purpose of this study is to determine whether a 10-day course of therapy with orally administered VCH-759 given at 400-mg, 600-mg or 800-mg three times daily can effectively reduce the amount of circulating virus (i.e., viral…
- Trial name
- NCT00389298
- Testing
- VCH-759 (BCH-27759)
- Where
- 4 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Healthy
Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects
Study to evaluate the safety and tolerability of single ascending doses and multiple ascending doses of VX-509 administered to healthy male and female subjects
- Trial name
- NCT00789126
- Testing
- VX-509
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatic Insufficiency
Study of Telaprevir in Subjects With Hepatic Impairment
The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.
- Trial name
- NCT00509210
- Testing
- telaprevir (VX-950)
- Where
- United States
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Hepatitis
Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
This trial is designed to test whether or not the addition of merimepodib (MMPD) to the standard therapy of pegylated interferon and ribavirin will result in a positive treatment response for people who have not previously…
- Trial name
- NCT00088504
- Testing
- Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®)
- Where
- 67 sites in United States
- Volunteers
- 315 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C
VX-950 and Peginterferon for Hepatitis C
VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.
- Trial name
- NCT00251199
- Testing
- VX-950, peginterferon
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.
- Trial name
- NCT00262483
- Testing
- VX-950, ribavirin, peginterferon alfa-2a
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 12 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Rheumatoid Arthritis
Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
The purpose of this study is to assess the clinical activity and safety of two doses of VX-702 compared to placebo in subjects with moderate to severe Rheumatoid Arthritis.
- Trial name
- NCT00205478
- Testing
- VX-702
- Where
- 43 sites in Bulgaria, Croatia and 7 more
- Volunteers
- 300 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Rheumatoid Arthritis
A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.
- Trial name
- NCT00395577
- Testing
- VX-702
- Where
- 17 sites in Bulgaria, Croatia and 4 more
- Volunteers
- 120 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Psoriasis
Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765
To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis treated for 28 days.
- Trial name
- NCT00205465
- Testing
- VX-765
- Volunteers
- 64 people
- Sponsor
- Vertex Pharmaceuticals Incorporated